Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Daiken Medical CoTSE:7775 +0.24%62 EBITDA Margin % is 13.60% as of Mar. 2026, which is 21% below its 10-year median of 17.11. GuruFocus rates TSE:7775 with a GF Score™ of 62/100 and a GF Value™ of 円541.84 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 815 Medical Devices & Instruments companies, Daiken Medical Co ranks better than 64.42% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Daiken Medical Co's EBITDA for the
six
months ended in Mar. 2026 was 円712 Mil. Daiken Medical Co's Revenue for the
six
months ended in Mar. 2026 was 円5,233 Mil. Therefore, Daiken Medical Co's EBITDA margin for the quarter that ended in Mar. 2026 was 13.60%.
Daiken Medical Co (TSE:7775) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Daiken Medical Co EBITDA Margin % Related Terms
Daiken Medical Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Daiken Medical Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7775 vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Daiken Medical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiken Medical Co EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Daiken Medical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Daiken Medical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Daiken Medical Co (TSE:7775) has a EBITDA Margin % of 13.60% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Daiken Medical Co and its competitors. This is 21% below median its historical median of 17.11. Over the past decade, Daiken Medical Co's EBITDA Margin % has ranged from 14.19 to 22.35. According to the industry distribution chart, Daiken Medical Co ranks #290 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 35.6%.
Is Daiken Medical Co's EBITDA Margin % too high?
Daiken Medical Co's current EBITDA Margin % of 13.60% is 21% below median its 10-year median of 17.11. Over the past 10 years, this metric has ranged from a low of 14.19 to a high of 22.35. The Medical Devices & Instruments industry median EBITDA Margin % is 7.52. Daiken Medical Co's value of 13.60% is 80.9% above this industry median. Based on the distribution chart, Daiken Medical Co ranks #290 out of 815 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Daiken Medical Co has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Daiken Medical Co's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Daiken Medical Co ranks #290 out of 815 companies for EBITDA Margin %. This puts Daiken Medical Co in the upper half of its industry. The industry median EBITDA Margin % is 7.52. Daiken Medical Co's value of 13.60% is 80.9% above this benchmark. Historically, Daiken Medical Co's own EBITDA Margin % has ranged from 14.19 to 22.35 over the past decade. While the company's 10-year median is 17.11 vs. the industry median of 7.52, Daiken Medical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.52, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Daiken Medical Co's current EBITDA Margin % of 13.60% is 80.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Daiken Medical Co and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daiken Medical Co's current EBITDA Margin % is 13.60%, which is 21% below median its own 10-year median of 17.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiken Medical Co stock overvalued right now?
Based on GuruFocus' analysis, Daiken Medical Co (TSE:7775) is currently considered Modestly Undervalued. The stock's GF Value™ is 円541.84, compared to a current price of 円426.00 — trading 21.4% below its estimated fair value. The current EBITDA Margin % is 13.60%, which is 21% below median its 10-year median of 17.11 and 80.9% above the Medical Devices & Instruments industry median of 7.52. Daiken Medical Co's overall GF Score™ is 62/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Daiken Medical Co (TSE:7775), the current EBITDA Margin % is 13.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Daiken Medical Co (TSE:7775) Overvalued in 2026?
Based on GuruFocus' analysis, Daiken Medical Co stock appears to be undervalued.
The current stock price of 円426.00 is trading 21.4% below its estimated GF Value™ of 円541.84.
GuruFocus considers Daiken Medical Co to be Modestly Undervalued.
Key valuation signals for TSE:7775:
EBITDA Margin %: 13.60% (21% below median its 10-year median of 17.11)
GF Value™: 円541.84 vs. price of 円426.00 (21.4% below fair value)
Industry Position: 80.9% above the Medical Devices & Instruments median (#290 of 815)
No single metric tells the full story. See the TSE:7775 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Daiken Medical Co Ltd manufactures and sells medical equipment. The product line includes - Coopdech syrinjector, Coopdech Syrinjector PCA device, Coopdech Balloonjector, Coopdech Endobronchial blocker tube, Coopdech double-lumen endobronchial tube, Fit fix suction container system, Wet disinfectant mat, and others.
62GF Score
Get the complete analysis for TSE:7775
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7775 has been successfully added to your 
